Navigation Links
HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock

FRAMINGHAM, Mass. and SYDNEY, March 12, 2013 /PRNewswire/ --  HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of 1,500,000 shares of common stock at a price per share of $86.45 pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC").  HeartWare also granted the underwriters an option to purchase up to an additional 225,000 shares to cover over-allotments, if any.

HeartWare intends to use the net proceeds from the offering for working capital and general corporate purposes, including, but not limited to, research and development, expansion of manufacturing capabilities, selling and marketing activities, capital investments in information systems, facilities and infrastructure, and general and administrative support functions to support growth and the acquisition or licensing of or investment in complementary products, technologies or businesses.

J.P. Morgan Securities LLC is acting as the sole book-running manager for the offering.  Canaccord Genuity Inc., Credit Suisse Securities (USA) LLC and Lazard Capital Markets LLC are acting as co-managers of the offering.  Perella Weinberg Partners served as independent capital markets advisor to HeartWare on this offering.

The offering does not require the prior approval of HeartWare's stockholders under the requirements of the Australian Stock Exchange.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. The offering will be made only by means of a prospectus and the related prospectus supplement. Before you invest, you should read the prospectus and the related prospectus supplement and any other document HeartWare has filed with the SEC for more complete information about HeartWare and the offering. You may get these documents for free by visiting EDGAR on the SEC Website at Alternatively, copies of the prospectus and the related prospectus supplement can be obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by calling 1-866-803-9204.

About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.

Forward-Looking Statements
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.  All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the commercial launch of the HeartWare® Ventricular Assist System in the U.S., continued support from international customers, progress of clinical trials and post-approval studies, regulatory status, research and development activities, commercialization strategies and the use of proceeds from this offering.  Management believes that these forward-looking statements are reasonable as and when made.  However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made.  HeartWare does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  HeartWare may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.  Forward-looking statements are subject to a number of risks and uncertainties, including without limitation those described in Part I, Item 1A. "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission.  We may update our risk factors from time to time in Part II, Item 1A "Risk Factors" in our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings with the Securities and Exchange Commission.

For further information:
Christopher Taylor
HeartWare International, Inc.
Phone: +1 508 739 0864


SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International, Inc. Announces Public Offering of Common Stock
2. HeartWare Presentation at the Barclays Capital 2013 Global Healthcare Conference To Be Webcast
3. HeartWare Presentation At Raymond James 34th Annual Institutional Investors Conference To Be Webcast
4. HeartWare International Reports Fourth Quarter 2012 Revenue Of $32.7 Million; Full Year 2012 Revenue Of $110.9 Million
5. HeartWare Schedules Fourth Quarter Conference Call and Webcast
6. HeartWare Presentation at Leerink Swann Global Healthcare Conference to be Webcast
7. HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
8. HeartWare Presentation At The 24th Annual Piper Jaffray Healthcare Conference To Be Webcast
9. HeartWare Presentation At The Lazard Capital Markets 9th Annual Healthcare Conference To Be Webcast
10. HeartWare Reports Third Quarter 2012 Results
11. HeartWare Schedules Third Quarter Conference Call And Webcast
Post Your Comments:
(Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... now treating sleep apnea using cutting-edge Oventus O2Vent technology. As many ... sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer significant ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
Breaking Medicine News(10 mins):